EP1358308B1 - Verkapselung von verbindungen in vesikeln - Google Patents

Verkapselung von verbindungen in vesikeln Download PDF

Info

Publication number
EP1358308B1
EP1358308B1 EP01998143A EP01998143A EP1358308B1 EP 1358308 B1 EP1358308 B1 EP 1358308B1 EP 01998143 A EP01998143 A EP 01998143A EP 01998143 A EP01998143 A EP 01998143A EP 1358308 B1 EP1358308 B1 EP 1358308B1
Authority
EP
European Patent Office
Prior art keywords
polymer
vesicle
vesicles
block
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP01998143A
Other languages
English (en)
French (fr)
Other versions
EP1358308A1 (de
Inventor
Thomas Hoenger Callisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Novozymes AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes AS filed Critical Novozymes AS
Publication of EP1358308A1 publication Critical patent/EP1358308A1/de
Application granted granted Critical
Publication of EP1358308B1 publication Critical patent/EP1358308B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0039—Coated compositions or coated components in the compositions, (micro)capsules
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38672—Granulated or coated enzymes

Definitions

  • the invention relates to compositions comprising enzymes encapsulated in synthetic polymer based vesicles, such as detergent compositions.
  • EP 724876 discloses a method of entrapping a water-soluble or -insoluble substance in vesicles formed from certain organosilicon compounds composed of surface active siloxanes.
  • WO 99/27907 discloses a method of encapsulating sensitive compounds in lipid based multilamellar vesicles.
  • vesicles formed from synthetic polymers can be used for encapsulation of enzymes in order to protect the enzymes from the chemical environment in which they are used.
  • composition comprising an enzyme encapsulated in a vesicle, wherein the vesicle comprises at least 50 %(w/w) of a synthetic polymer as a vesicle forming agent; and wherein the synthetic polymer is an amphiphilic di- or tri-block-co-polymer; and wherein each domain of the di- or tri-block-co-polymer consists of at least 10 monomers selected from the monomer-classes ethyleneoxide, propyleneoxide, ethylethylene, acrylic acid, and vinyl amine.
  • a method for preventing an enzyme from reacting with other compounds comprising encapsulating the compound in a vesicle, wherein the vesicle comprises at least 50 %(w/w) of a di- or tri-block-co-polymer as a vesicle forming agent, and wherein the di- or tri-block-co-polymer is a polymer of monomers selected from the monomer-classes ethyleneoxide, propyleneoxide, ethylethylene, acrylic acid, and vinyl amine.
  • enzyme-containing vesicles are used for improving the stability of the enzymes, or for preventing the enzymes from reacting with other compounds.
  • Suitable synthetic polymers for forming the vesicles of the invention are combinations of synthetic polymers of the monomer-classes ethyleneoxide, propyleneoxide, ethylethylene, acrylic acid, and vinyl amine. Homo-polymers of these monomers (such as polyethyleneoxide - also known as PEG - and polyethylethylene) are covalently linked to form di- or tri-block-co-polymers.
  • Di-block-co-polymers self-associate as bilayer phases while tri-block-co-polymers, e.g., composed of a hydrophobic central domain connected to hydrophilic domains at each end, form single-molecular smectic layers with a hydrophobic core.
  • Increasing the width of the interior hydrophobic core would typically bring about improved properties with respect to water permeability of the vesicular structure.
  • the stability of the layers is balanced by the choice of subunits, which make up the co-polymers.
  • vesicles it is possible to change the stability of the vesicles by cross-polymerization of the monomers or by incorporating tri-block-co-polymers into the bilayer structures or in general alloy the vesicle structure with minor components that modify the balance of forces in the structure.
  • preferred polymers are E040-EE37 (nomenclature as in Discher et al. (1999), Science, Vol. 284, pp. 1143-1146 ), EO40-EE74-EO40, E050-EE37 and Pluronics (such as L121), or combinations thereof.
  • Synthetic polymer is to be understood as a polymer, which is composed of synthetic homo-polymers, such as polyethyleneoxide, polypropylenoxide, or polyethylethylene. Subunits or domains may consist of hetero-polymers of monomers rendering an overall hydrophilic or hydrophobic stretch.
  • synthetic is to be understood as a non-naturally occurring compound.
  • the polymers are uncharged at the pH of the composition.
  • Each homo-polymer (domain) of the block-co-polymers consists of at least 10 monomers, preferably at least 20 monomers, more preferably at least 30 monomers, and most preferably at least 40 monomers.
  • the domains may comprise 30-50 monomers of the ethyleneoxide or propyleneoxide type; and in tri-block-co-polymers the central domain may comprise 60-100 monomers of the ethyleneoxide or propyleneoxide type with the exterior domains comprising 30-50 monomers.
  • the polymers are not amphiphilic lipids, such as phospholipids.
  • Vesicles are to be understood as uni- or multi-lamellar structures as defined in J.N. Israelachvili, Intermolecular and Surface Forces, 2nd edition (1992), Academic Press, San Diego CA, USA .
  • the vesicular structure may be of:
  • the vesicles may also be part of a suspension or a multiple emulsion with a bulk water-like phase or a bulk oil-like phase.
  • the molecular constituents would primarily be of an amphiphilic character with domains of high and low water solubility (the latter often translates into high oil solubility). Minor components may have only one of the previous types of domains. In case of 1), the main class of molecules would have two domains with oppositely preferred solvent. In case of 2) the dominant part of molecules would have three domains with the center-domain of opposite solvent-preference to the external domains. The orientation of the molecular domains depends on the solvent for the vesicles (water-like or oil-like bulk phase).
  • the intermolecular interactions in the vesicles may be of covalent and non-covalent origin.
  • the molecules and the molecular building blocks may be of natural or synthetic origin; classes included are lipids, sugars, amino acids, nucleic acids, and synthetic polymers of building blocks, such as ethyleneoxide, propyleneoxide, and butyleneoxide.
  • Reactive compounds may be incorporated in the vesicle structure to generate cross-linking among the molecules.
  • the vesicle is an aqueous compartment enclosed by a membrane comprising one or more layers, where the layers have an inner hydrophobic domain and an outer hydrophilic domain.
  • the vesicles of the invention may suitably comprise at least 50%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, most preferably at least 90%, and in particular 95% of synthetic polymers as vesicle forming agents.
  • the vesicles are composed of 100% of synthetic polymers as vesicle forming agents.
  • the average diameter of the polymer-based vesicles are 0.1 ⁇ m to 500 ⁇ m, preferably 0.1 ⁇ m to 100 ⁇ m, more preferably 0.1 ⁇ m to 10 ⁇ m.
  • the vesicles may be uni-lamellar or have an onion-like structure, such as a multi-lamellar structure.
  • Polymer-based vesicles are particularly suitable for use in surfactant solutions, as compared to lipid vesicles (liposomes), due to a better stability towards surfactants and lower water permeability. Polymer-based vesicles are also referred to as polymersomes (in contrast to liposomes).
  • the polymer-based vesicles may be prepared by treating a suspension of polymers and compounds (for encapsulation) with ultra-sonic irradiation, or extruding the suspension through a porous membrane (filters) of desired pore size. Ultra-sonic treatment and extrusion may be combined or exchanged by methods such as reverse phase dialysis. Subsequently, the vesicles with the entrapped compounds may be concentrated by centrifugation or dialysis.
  • Suitable compounds for being encapsulated in the polymer-based vesicles are enzymes, such as proteases, lipases, cutinases, amylases, carbohydrases, cellulases, pectinases, mannanases, arabinases, galactanases, xylanases, oxidases, e.g., laccases, and/or peroxidases (such as haloperoxidases).
  • enzymes such as proteases, lipases, cutinases, amylases, carbohydrases, cellulases, pectinases, mannanases, arabinases, galactanases, xylanases, oxidases, e.g., laccases, and/or peroxidases (such as haloperoxidases).
  • the enzymes in the context of the present invention may be any enzyme or combination of different enzymes. Accordingly, when reference is made to "an enzyme” this will in general be understood to include both a single enzyme and a combination of more than one enzyme.
  • enzyme variants are included within the meaning of the term "enzyme”. Examples of such enzyme variants are disclosed, e.g., in EP 251446 (Genencor), WO 91/00345 (Novo Nordisk A/S), EP 525610 (Solvay) and WO 94/02618 (Gist-Brocades NV).
  • the enzyme classification employed in the present specification and claims is in accordance with Recommendations (1992) of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology, Academic Press, Inc., 1992 .
  • the types of enzymes which may appropriately be incorporated in the polymer-based vesicles include oxidoreductases (EC 1.-.-.-), transferases (EC 2.-.-.-), hydrolases (EC 3.-.-.-), lyases (EC 4.-.-.-), isomerases (EC 5.-.-.-) and ligases (EC 6.-.-.-).
  • Preferred oxidoreductases in the context of the invention are peroxidases (EC 1.11.1), laccases (EC 1.10.3.2) and glucose oxidases (EC 1.1.3.4), while preferred transferases are transferases in any of the following sub-classes:
  • a most preferred type of transferase in the context of the invention is a transglutaminase (protein-glutamine ⁇ -glutamyltransferase; EC 2.3.2.13).
  • transglutaminases are described in WO 96/06931 (Novo Nordisk A/S).
  • Preferred hydrolases in the context of the invention are: Carboxylic ester hydrolases (EC 3.1.1.-) such as lipases (EC 3.1.1.3); phytases (EC 3.1.3.-), e.g. 3-phytases (EC 3.1.3.8) and 6-phytases (EC 3.1.3.26); glycosidases (EC 3.2, which fall within a group denoted herein as "carbohydrases”), such as ⁇ -amylases (EC 3.2.1.1); peptidases (EC 3.4, also known as proteases); and other carbonyl hydrolases].
  • Carboxylic ester hydrolases EC 3.1.1.-
  • lipases EC 3.1.1.3
  • phytases EC 3.1.3.-
  • 3-phytases EC 3.1.3.8
  • 6-phytases EC 3.1.3.26
  • glycosidases EC 3.2, which fall within a group denoted herein as "carbohydra
  • carbohydrase is used to denote not only enzymes capable of breaking down carbohydrate chains (e.g. starches) of especially five- and six-membered ring structures (i.e. glycosidases, EC 3.2), but also enzymes capable of isomerizing carbohydrates, e.g. six-membered ring structures such as D-glucose to five-membered ring structures such as D-fructose.
  • Carbohydrases of relevance include the following (EC numbers in parentheses): ⁇ -amylases (3.2.1.1), ⁇ -amylases (3.2.1.2), glucan 1,4- ⁇ -glucosidases (3.2.1.3), cellulases (3.2.1.4), endo-1,3(4)- ⁇ -glucanases (3.2.1.6), endo-1,4- ⁇ -xylanases (3.2.1.8), dextranases (3.2.1.11), chitinases (3.2.1.14), polygalacturonases (3.2.1.15), lysozymes (3.2.1.17), ⁇ -glucosidases (3.2.1.21), ⁇ -galactosidases (3.2.1.22), ⁇ -galactosidases (3.2.1.23), amylo-1,6-glucosidases (3.2.1.33), xylan 1,4- ⁇ -xylosidases (3.2.1.37), glucan end
  • oxidoreductases examples include GluzymeTM (enzyme available from Novozymes A/S).
  • proteases examples include KannaseTM, EverlaseTM, EsperaseTM, AlcalaseTM, NeutraseTM, DurazymTM, SavinaseTM, PyraseTM, Pancreatic Trypsin NOVO (PTN), Bio-FeedTM Pro and Clear-LensTM Pro (all available from Novozymes A/S, Bagsvaerd, Denmark).
  • proteases include MaxataseTM, MaxacalTM, MaxapemTM, OpticleanTM and PurafectTM (available from Genencor International Inc. or Gist-Brocades).
  • lipases examples include LipoprimeTM LipolaseTM, LipolaseTM Ultra, LipozymeTM, PalataseTM, NovozymTM 435 and LecitaseTM (all available from Novozymes A/S).
  • lipases include LumafastTM ( Pseudomonas mendocina lipase from Genencor International Inc.); LipomaxTM ( Ps. pseudoalcaligenes lipase from Gist-Brocades/Genencor International Inc.; and Bacillus sp. lipase from Solvay enzymes. Further lipases are available from other suppliers.
  • carbohydrases examples include Alpha-GalTM, Bio-FeedTM Alpha, Bio-FeedTM Beta, Bio-FeedTM Plus, Bio-FeedTM Plus, NovozymeTM 188, CelluclaStTM, CellusoftTM, CeremylTM, CitrozymTM, DenimaxTM, DezymeTM, DextrozymeTM, FinizymTM, FungaMylTM, GamanaseTM, GlucanexTM, LactozymTM, MaltogenaseTM, PentopanTM, PectinexTM, PromozymeTM, PulpzymeTM, NovamylTM, TermamylTM, AMGTM (Amyloglucosidase Novo), MaltogenaseTM, SweetzymeTM and AquazymTM (all available from Novozymes A/S). Further carbohydrases are available from other suppliers.
  • the composition of the invention may be a surfactant containing composition, (such as a detergent composition), a cosmetic composition or a personal care composition, such as lotions (e.g. eye lotions), liquids, creams, gels, pastes, ointments (e.g. eye ointments), soaps, shampoos, conditioners, antiperspirants, deodorants, mouth wash, nasal sprays, or contact lens products.
  • a surfactant containing composition such as a detergent composition
  • a cosmetic composition or a personal care composition such as lotions (e.g. eye lotions), liquids, creams, gels, pastes, ointments (e.g. eye ointments), soaps, shampoos, conditioners, antiperspirants, deodorants, mouth wash, nasal sprays, or contact lens products.
  • composition of the invention may be formulated as a solid or a liquid.
  • the composition When formulated as a liquid, the composition is typically an aqueous composition.
  • the composition When formulated as a solid, the composition is typically a powder, a granulate, a paste or a gelled product.
  • the composition of the invention is a liquid surfactant containing composition.
  • Suitable surfactants for being incorporated in the composition may be non-ionic (including semi-polar), anionic, cationic and/or zwitterionic.
  • the surfactants are preferably anionic or non-ionic.
  • the surfactants are typically present in the composition at a concentration of from 1% to 90% (preferably 5% to 60%, more preferably 10% to 50%) by weight, but the composition may also contain close to 100% surfactant or consist of 100% surfactant.
  • the pH of the composition is pH 4-11, preferably pH 6-11, more preferably in the alkaline range (such as pH 7-10), and particularly pH 8-10, as determined in a 1% aqueous solution.
  • the composition will usually contain from about 1% to about 80%, preferably about 2% to about 50%, and more preferably about 5% to about 40% by weight of an anionic surfactant, such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid or soap.
  • an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid or soap.
  • the composition will usually contain from about 1% to about 80%, preferably about 2% to about 50%, and more preferably about 5% to about 40% by weight of a non-ionic surfactant, such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine (“glucamides”).
  • a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine (“glucamides”).
  • the surfactant containing composition may be a detergent composition.
  • it may be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dishwashing operations.
  • the detergent composition may comprise one or more other enzymes such as a protease, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a laccase, and/or a peroxidase.
  • enzymes such as a protease, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a laccase, and/or a peroxidase
  • the properties of the chosen enzyme(s) should be compatible with the detergent, (i.e. pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.
  • proteases include those of animal, vegetable or microbial origin. Microbial origin is preferred. Chemically modified or protein engineered mutants are included.
  • the protease may be a serine protease or a metallo protease, preferably an alkaline microbial protease or a trypsin-like protease.
  • alkaline proteases are subtilisins, especially those derived from Bacillus, e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279 ).
  • trypsin-like proteases are trypsin (e.g. of porcine or bovine origin) and the Fusarium protease described in WO 89/06270 and WO 94/25583 .
  • Examples of useful proteases are the variants described in WO 92/19729 , WO 98/20115 , WO 98/20116 , and WO 98/34946 , especially the variants with substitutions in one or more of the following positions: 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 194, 206, 218, 222, 224, 235 and 274.
  • Preferred commercially available protease enzymes include AlcalaseTM, SavinaseTM, PrimaseTM, EverlaseTM, EsperaseTM, and KannaseTM (Novozymes A/S), MaxataseTM, MaxacalTM, MaxapemTM, ProperaseTM, PurafectTM, Purafect OxPTM, FN2TM, and FN3TM (Genencor International Inc.).
  • Lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful lipases include lipases from Humicola (synonym Thermomyces ), e.g. from H . lanuginosa ( T. lanuginosus ) as described in EP 258 068 and EP 305 216 or from H . insolens as described in WO 96/13580 , a Pseudomonas lipase, e.g. from P. alcaligenes or P . pseudoalcaligenes ( EP 218 272 ), P. cepacia ( EP 331 376 ), P.
  • lipase variants such as those described in WO 92/05249 , WO 94/01541 , EP 407 225 , EP 260 105 , WO 95/35381 , WO 96/00292 , WO 95/30744 , WO 94/25578 , WO 95/14783 , WO 95/22615 , WO 97/04079 and WO 97/07202 .
  • LipolaseTM Lipolase UltraTM
  • LipoprimeTM Novozymes A/S
  • Amylases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, ⁇ -amylases obtained from Bacillus, e.g. a special strain of B . licheniformis , described in more detail in GB 1,296,839 .
  • Examples of useful amylases are the variants described in WO 94/02597 , WO 94/18314 , WO 96/23873 , and WO 97/43424 , especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408, and 444.
  • amylases are DuramylTM, TermamylTM, FungamylTM and BANTM (Novozymes A/S), RapidaseTM and PurastarTM (Genencor International Inc.).
  • Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera Bacillus, Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium, e.g. the fungal cellulases produced from Humicola insolens, Myceliophthora thermophila and Fusarium oxysporum disclosed in US 4,435,307 , US 5,648,263 , US 5,691,178 , US 5,776,757 and WO 89/09259 .
  • cellulases are the alkaline or neutral cellulases having colour care benefits.
  • Examples of such cellulases are cellulases described in EP 0 495 257 , EP 0 531 372 , WO 96/11262 , WO 96/29397 , WO 98/08940 .
  • Other examples are cellulase variants such as those described in WO 94/07998 , EP 0 531 315 , US 5,457,046 , US 5,686,593 , US 5,763,254 , WO 95/24471 , WO 98/12307 and PCT/DK98/00299 .
  • cellulases include CelluzymeTM, and CarezymeTM (Novozymes A/S), ClazinaseTM, and Puradax HATM (Genencor International Inc.), and KAC-500(B)TM (Kao Corporation).
  • Peroxidases/Oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from Coprinus , e.g. from C. cinereus , and variants thereof as those described in WO 93/24618 , WO 95/10602 , and WO 98/15257 .
  • the detergent may be a liquid detergent, and the liquid detergent may be aqueous (typically containing up to 70 % water and 0-30 % organic solvent) or non-aqueous.
  • the detergent may contain 0-65 % of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).
  • a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).
  • the detergent may comprise one or more polymers.
  • examples are carboxymethylcellulose, poly(vinylpyrrolidone), poly (ethylene glycol), poly(vinyl alcohol), poly(vinylpyridine-N-oxide), poly(vinylimidazole), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.
  • the detergent may contain a bleaching system, which may comprise a H 2 O 2 source, such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetylethylenediamine or nonanoyloxybenzenesulfonate.
  • a bleaching system may comprise peroxyacids of e.g. the amide, imide, or sulfone type.
  • the enzyme(s) of the detergent composition may be stabilized using conventional stabilizing agents, e.g., a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid.
  • a polyol such as propylene glycol or glycerol
  • a sugar or sugar alcohol lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid.
  • the detergent may also contain other conventional detergent ingredients such as e.g. fabric conditioners including foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.
  • fabric conditioners including foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.
  • any enzyme in particular enzymes encapsulated in the polymer-based vesicles, may be added in an amount corresponding to 0.01-100 mg of enzyme protein per liter of wash liquor, preferably 0.05-10 mg of enzyme protein per liter of wash liquor, more preferably 0.1-5 mg of enzyme protein per liter of wash liquor, and most preferably 0.1-1 mg of enzyme protein per liter of wash liquor.
  • the method of the invention may be used for protection of a compound in a surfactant solution, such as separation of incompatible compounds. Incompatibility between compounds may result in reduced storage stability, reduced shelf life, and degradation. In the case of biologically active compounds, incompatibility between compounds may result in loss of biological activity - e.g. enzymes may loose their enzymatic activity.
  • the method of the invention may also be used advantageously for controlled release of the encapsulated compound.
  • the composition with the vesicle is diluted, osmotic swelling will eventually result in the rupture of the vesicle, and the encapsulated compound will be released into the solution.
  • the vesicle may also be ruptured by a mechanical treatment, such as being squeezed through a suitable filter.
  • Chemicals used as buffers and substrates were commercial products of at least reagent grade.
  • DMPC diristoylphosphatidylcholine
  • HPLC grade from Avanti Polar Lipids
  • the suspensions were vigorously mixed in an ultrasound bath at 70 degrees Celsius for 30 minutes. Vesicles were produced according to the manufactures specifications in a T.001 10 ml thermo-barrel Extruder from NORTHERN LIPIDS INC., Vancouver BC, Canada. The suspensions were initially passed three times through 400 nm filter; hereafter five times through 200 nm filters. Operation pressure was 5-10 atmospheres at 50 degrees Celsius.
  • the extruded vesicles were places in dialysis tubes (with a molecular cut-off of 100 kDa, product number 235071 from Spectra). Buffer without the substance intended for encapsulation was used as exterior medium.
  • the concentrated vesicle suspensions were analyzed by differential scanning calorimetry to ascertain the properties of the vesicles and the amount of encapsulated enzyme.
  • the encapsulated amylase was also quantified according to a standard alpha-amylase assay (the Phadebas method).
  • the suspensions containing the enriched encapsulated substance, and the control solution are added separately to solutions containing from 0.1 %(w/w) to 10 %(w/w) of various mixtures of linear alkylbenzenesulphonate (Marlon AS3 obtainable from Hüls) and alcohol ethoxylate (Neodol 25-7 obtainable from Shell Chemicals), ranging from exclusively linear alkylbenzenesulphonate to exclusively alcohol ethoxylate.
  • Bacillus Lentus subtilisin 309 protease (available as Savinase® from Novozymes A/S, Denmark) is added and the samples are incubated for another 24 hours. This is done to degrade (inactivate) the amylase released from the vesicles which have been degraded during the incubation period.
  • the samples are now heated to 100 degrees Celsius for 10 seconds to stop the proteolytic activity and to release all remaining amylase activity from the intact vesicles. Full removal of protease activity is confirmed by a standard protease assay. The samples are then transferred to the amylase assay described above for evaluation of the residual amount of encapsulated amylase in the vesicles.
  • the vesicles composed of amphiphiles B, C and D are more stable in a solution containing high concentrations of surfactant compared to traditional vesicles composed of DMPC.
  • a higher amount of active amylase is retained after storage when the vesicles are composed of amphiphiles B, C and D than when the vesicles are composed of DMPC (amphiphile A in Example 1).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Detergent Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (10)

  1. Zusammensetzung, umfassend ein in ein Vesikel eingekapseltes Enzym, wobei das Vesikel mindestens 50 % (Gew./Gew.) eines synthetischen Polymers als ein Vesikel bildendes Mittel umfasst; und wobei das synthetische Polymer ein amphiphiles Di- oder Tri-Blockcopolymer ist; und wobei jede Domäne des Di- oder Tri-Blockcopolymers aus mindestens 10 Monomeren, ausgewählt aus den Monomerklassen Ethylenoxid, Propylenoxid, Ethylethylen, Acrylsäure und Vinylamin, besteht.
  2. Zusammensetzung nach Anspruch 1, welche ein anionisches oder nicht ionisches oberflächenaktives Mittel einschließt.
  3. Zusammensetzung nach einem beliebigen der Ansprüche 1-2, wobei jede Domäne des Blockcopolymers ein Homopolymer ist.
  4. Zusammensetzung nach einem beliebigen der Ansprüche 1-3, wobei das Vesikel ein wässriger Raum ist, umschlossen durch eine Membran, umfassend eine oder mehrere Schichten, wobei die Schichten eine innere hydrophobe Domäne und eine äußere hydrophile Domäne aufweisen.
  5. Verfahren zum Verhindern des Reagierens von einem Enzym mit anderen Verbindungen, umfassend das Einkapseln der Verbindung in ein Vesikel, wobei das Vesikel mindestens 50 % (Gew./Gew.) eines Di- oder Tri-Blockcopolymers als ein Vesikel bildendes Mittel umfasst, und wobei das Di- oder Tri-Blockcopolymer ein Polymer von Monomeren, ausgewählt aus den Monomerklassen Ethylenoxid, Propylenoxid, Ethylethylen, Acrylsäure und Vinylamin, ist.
  6. Verfahren nach Anspruch 5, wobei jede Domäne des Blockcopolymers ein Homopolymer ist.
  7. Verfahren nach einem beliebigen der Ansprüche 5-6, wobei das Vesikel ein wässriger Raum ist, umschlossen durch eine Membran, umfassend eine oder mehrere Schichten, wobei die Schichten eine innere hydrophobe Domäne und eine äußere hydrophile Domäne aufweisen.
  8. Verwendung eines Enzym enthaltenden Vesikels zum Verhindern des Reagierens des Enzyms mit anderen Verbindungen, wobei das Vesikel mindestens 50 % (Gew./Gew.) eines Di- oder Tri-Blockcopolymers als ein Vesikel bildendes Mittel umfasst, und wobei das Di- oder Tri-Blockcopolymer ein Polymer von Monomeren, ausgewählt aus den Monomerklassen Ethylenoxid, Propylenoxid, Ethylethylen, Acrylsäure und Vinylamin, ist.
  9. Verwendung nach Anspruch 8, wobei jede Domäne des Blockcopolymers ein Homopolymer ist.
  10. Verwendung nach einem beliebigen der Ansprüche 8-9, wobei das Vesikel ein wässriger Raum ist, umschlossen durch eine Membran, umfassend eine oder mehrere Schichten, wobei die Schichten eine innere hydrophobe Domäne und eine äußere hydrophile Domäne aufweisen.
EP01998143A 2000-12-01 2001-11-30 Verkapselung von verbindungen in vesikeln Expired - Lifetime EP1358308B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200001810 2000-12-01
DKPA200001810 2000-12-01
PCT/DK2001/000798 WO2002044313A1 (en) 2000-12-01 2001-11-30 Encapsulation of compounds in vesicles

Publications (2)

Publication Number Publication Date
EP1358308A1 EP1358308A1 (de) 2003-11-05
EP1358308B1 true EP1358308B1 (de) 2010-01-20

Family

ID=8159884

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01998143A Expired - Lifetime EP1358308B1 (de) 2000-12-01 2001-11-30 Verkapselung von verbindungen in vesikeln

Country Status (5)

Country Link
EP (1) EP1358308B1 (de)
AT (1) ATE455839T1 (de)
AU (1) AU2002220522A1 (de)
DE (1) DE60141167D1 (de)
WO (1) WO2002044313A1 (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576760A (en) * 1969-06-13 1971-04-27 Nat Patent Dev Corp Water soluble entrapping
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
US5385959A (en) * 1992-04-29 1995-01-31 Lever Brothers Company, Division Of Conopco, Inc. Capsule which comprises a component subject to degradation and a composite polymer
FR2695034B1 (fr) * 1992-09-01 1994-10-07 Oreal Composition cosmétique ou pharmaceutique comprenant en association une peroxydase et un agent anti-oxygène singulet.
DE4238779A1 (de) * 1992-11-12 1994-05-19 Max Delbrueck Centrum Lyotrophe Mesophasen und ihre Anwendung in der Pharmazie, der Kosmetik und der Dermatologie
ES2147217T3 (es) * 1993-11-12 2000-09-01 Unilever Nv Composicion detergente.
US5958448A (en) * 1995-01-13 1999-09-28 Dow Corning Corporation Siloxane MQ resin vesicles and entrapment
DE19537415A1 (de) * 1995-10-09 1997-04-10 New Standard Gmbh Micro Wirkstoff-Perlen
AU1203697A (en) * 1995-12-29 1997-07-28 Allied Colloids Limited Enzyme-containing particles and liquid detergent concentrate
FR2751222B1 (fr) * 1996-07-16 1998-10-09 Capsulis Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique
FR2771636B1 (fr) * 1997-12-01 2001-06-15 Capsulis Procede perfectionne pour eviter la degradation d'un principe actif

Also Published As

Publication number Publication date
EP1358308A1 (de) 2003-11-05
DE60141167D1 (de) 2010-03-11
ATE455839T1 (de) 2010-02-15
WO2002044313A1 (en) 2002-06-06
AU2002220522A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
CN108350441B (zh) 多肽
EP2992076B1 (de) Mikroverkapselung von wasch und reinigungsmittelenzymen
CN106103710B (zh) 使用小胺进行的微囊化
EP2126027B1 (de) Enzymschaumbehandlung für wäsche
US20200190436A1 (en) Cleaning compositions and uses thereof
US8071345B2 (en) Stabilized subtilisin composition
US20020192792A1 (en) Laccase mutants
US11634665B2 (en) Detergent composition
EP2139979B1 (de) Stabile enzymlösungen und herstellungsverfahren
EP2004789A1 (de) Stabilisierte flüssige enzymzusammensetzung
CN107475235A (zh) 颗粒组合物
WO2007025549A1 (en) Stabilization of concentrated liquid enzyme additives
JP2022549712A (ja) 洗剤の持続可能性の改善のためのセルラーゼの使用
US20230287306A1 (en) Cleaning Composition
CN106661521B (zh) 洗涤剂组分的微囊化
Crutzen et al. Detergent enzymes: a challenge!
CN111770788B (zh) 使用氨基糖低聚物进行微囊化
US20020106511A1 (en) Encapsulation of compounds in vesicles
EP1358308B1 (de) Verkapselung von verbindungen in vesikeln
US6794350B2 (en) Reduction of malodor from laundry
EP1362089A1 (de) Verminderung von unangenehmen gerüchen von wäsche
AU2002231607A1 (en) Reduction of malodour from laundry

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030701

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040226

17Q First examination report despatched

Effective date: 20040226

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60141167

Country of ref document: DE

Date of ref document: 20100311

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100520

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100421

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20101021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100120

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20131108

Year of fee payment: 13

Ref country code: GB

Payment date: 20131127

Year of fee payment: 13

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20141130

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141201

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181128

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60141167

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200603